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Abstract
Background and Purpose—Current methods to estimate risk of radiation-induced lung 
toxicity (RILT) rely on dosimetric parameters. We aimed to improve prognostication by 
incorporating clinical and cytokine data, and to investigate how these factors may interact with the 
effect of mean lung dose (MLD) on RILT.
Materials and Methods—Data from 125 patients treated from 2004 to 2013 with definitive 
radiotherapy for stages I–III NSCLC on four prospective clinical trials were analyzed. Plasma 
levels of 30 cytokines were measured pretreatment, and at 2 and 4 weeks midtreatment. Penalized 
logistic regression models based on combinations of MLD, clinical factors, and cytokine levels 
were developed. Cross-validated estimates of log-likelihood and area under the receiver operating 
characteristic curve (AUC) were used to assess accuracy.
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Results—In prognosticating grade 3 or greater RILT by MLD alone, cross-validated log-
likelihood and AUC were −28.2 and 0.637, respectively. Incorporating clinical features and 
baseline cytokine levels increased log-likelihood to −27.6 and AUC to 0.669. Midtreatment 
cytokine data did not further increase log-likelihood or AUC. Of the 30 cytokines measured, 
higher levels of 13 decreased the effect of MLD on RILT, corresponding to a lower odds ratio for 
RILT per Gy MLD, while higher levels of 4 increased the association.
Conclusions—Although the added prognostic benefit from cytokine data in our model was 
modest, understanding how clinical and biologic factors interact with the MLD-RILT relationship 
represents a novel framework for understanding and investigating the multiple factors contributing 
to radiation-induced toxicity.
Introduction
Despite advances in conformal techniques, radiation-induced lung toxicity (RILT) remains a 
significant source of morbidity and mortality, occurring in 5–50% of patients treated with 
radiotherapy for lung cancer [1, 2]. Current methods to assess the risk of RILT are based on 
dose-volume parameters, such as mean lung dose (MLD) and the volume of lung receiving 
at least 20 Gy (V20) [3–7]. Such methods, however, are suboptimal for predicting risk in 
individual patients.
In addition to dosimetric variables, several patient-specific risk factors for RILT have been 
identified, including older age, coexisting lung disease, and specific chemotherapeutic 
agents [8–11]. While such factors are important to consider when assessing risk for RILT, a 
standardized, multi-factorial model is lacking.
Radiation-induced lung toxicity is in part regulated by inflammatory and fibrotic cytokines 
[12–15]. The most well-studied of these is transforming growth factor beta 1 (TGFβ1), 
which was first found to be associated with pneumonitis after autologous bone marrow 
transplantation for advanced breast cancer [16]. Subsequent studies showed radiation-
induced elevation of plasma levels of TGFβ1 to be associated with increased risk of 
radiation pneumonitis [17–23]. While other studies failed to demonstrate an independent 
predictive value of TGFβ1, this may have been due to improper sample handling [24–26]. In 
a meta-analysis of 7 studies, a ratio of posttreatment to pretreatment TGFβ1 >=1 was a 
significant predictor of RILT [27]. Studies combining cytokine and dosimetric data have also 
been promising, with two studies showing improved RILT prediction by combining 
posttreatment TGFβ1 levels with dosimetric variables [19, 28]. Attempts have been made to 
use TGFβ1 levels to direct treatment planning, and some success has been reported in the 
setting of dose escalation [29].
In addition to TGFβ1, low plasma levels of interleukin (IL) 8 [20, 26], and high levels of IL6 
[30, 31] and IL10 [30] have been found to correlate with lung toxicity, although these 
findings have not been consistent in all studies [20, 23]. Other cytokines, including tumor 
necrosis factor (TNF) α and IL1β, have failed to show prognostic value [20, 23].
The studies described above have primarily investigated the effect of clinical factors and 
cytokine levels on the risk of RILT directly. An alternative strategy would be to instead 
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model multiple variables as statistical interactions with the MLD-RILT association. Such an 
approach could provide a unique avenue for investigating the functions of various risk 
factors and could prove useful for understanding how different variables influence a 
patient’s tolerability of high-dose radiotherapy. Herein we describe development and 
evaluation of such a model.
Methods and Materials
Study Population
This work analyzed data from 4 prospective Institutional Review Board (IRB) approved 
lung-cancer studies: (1) a phase 1/2 study of radiation dose escalation with concurrent 
chemotherapy, (2–3) 2 consecutive studies using functional imaging and biomarkers to 
assess patient outcome, and (4) a study using midtreatment PET to guide individualized dose 
escalation. Included in this analysis were patients with stage I–III NSCLC treated with 
standard fractionation, i.e. not stereotactic body radiotherapy (SBRT). Details of these 
studies are shown in Supplemental Table 1. As part of these clinical trials, patients consented 
to have blood samples collected and analyzed for proteins for investigation of potential 
factors correlating with toxicity and treatment response. Specimen collection and analysis 
was approved by the IRB committee. All clinical data were prospectively collected. 
Smoking status was missing for 11 patients, which was handled via single imputation. 
Patients consented to receive treatment per these investigational protocols, as well as
Treatment Regimen
All patients were treated with definitive RT with or without sequential or concurrent 
chemotherapy. In cases of sequential treatment, chemotherapy was administered following 
radiotherapy. Radiation was delivered using three-dimensional conformal radiotherapy 
(3DCRT) as previously described [32]. Gross tumor volume included the primary tumor and 
any involved hilar or mediastinal lymph nodes, as determined by tissue diagnosis and/or 
positron emission tomography (PET)-CT. Uninvolved lymph node regions were not included 
in the clinical target volume. Lung dose volume histograms (DVHs) were generated using 
both lungs with exclusion of gross tumor volume [33]. For the dose-escalation trial, we 
constrained the lung normal tissue complication probability (NTCP) to < 15%, and for the 
adaptive trial we constrained NTCP to < 17.5% [34]. Tissue inhomogeneity corrections were 
applied for all plans.
Mean lung doses are reported in terms of equivalent to 2-Gy daily dosing (EQD2), as 
calculated via the linear quadratic model using an alpha/beta of 2.5. All doses were 
recomputed using modern dose calculations (AAA in Eclipse, Varian Medical Systems, Palo 
Alto, CA).
Cytokine Analysis
Cytokine measurements were performed in platelet-poor plasma samples at 3 time points: at 
baseline (within 2 weeks before the start of RT) and at 2 and 4 weeks during RT. Plasma 
samples were collected and prepared as previously described [21].
Hawkins et al. Page 3
Radiother Oncol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Plasma concentrations of 30 cytokines were measured: epidermal growth factor (EGF), 
eotaxin, fractalkine, granulocyte colony stimulating factor (GCSF), granulocyte macrophage 
colony stimulating factor (GMCSF), interferon α (IFNα), IL1α, IL1β, IL2, IL4, IL5, IL6, 
IL7, IL8, IL10, IL12 subunit 40 (IL12p40), IL12 p35 and p40 heterodimer (IL12p70), IL13, 
IL15, IL17, IL1 receptor antagonist (IL1RA), monocyte chemoattractant protein 1 (MCP1), 
macrophage inflammatory protein (MIP) 1α, MIP1β, soluble CD40 ligand (SCD40L), 
TGFα, TGFβ1, TNFα, and vascular endothelial growth factor (VEGF).
TGFβ1 levels were measured using enzyme-linked immunosorbent assay (ELISA) as 
previously described [20], while the other 29 cytokines were measured using luminex 
multiplex assay (xMAP plasma assay; Luminx, St. Charles, MO). All sample tests were run 
in duplicate. Some cytokine measurements fell below a lower limit of detection. We used an 
ad hoc methodology to detect and account for these censored measurements, which is 
described in the supplement.
Follow Up and Toxicity Evaluation
Patients were evaluated weekly during radiotherapy, with follow-up evaluation at 1 month 
after completion of RT, then every 3 months for 1 year, followed by every 6 months for 1 
additional year. At each follow-up, patients underwent a history and physical examination as 
well as chest computed tomography (CT). Radiation-induced lung toxicity, including 
radiation pneumonitis and clinical fibrosis, was evaluated and graded as previously 
described [4]. Grade 3 radiation pneumonitis or clinical fibrosis was defined as severe 
cough, dyspnea at rest, or oxygen requirement in the setting of radiographic evidence of 
pneumonitis or radiation fibrosis.
Statistical Modeling
We modeled the association between RILT and patient factors using logistic regression. 
Cytokine measurements were log transformed and all covariates were standardized to have 
mean zero and unit standard deviation prior to modeling. Baseline and change in cytokine 
measurements were assumed to modify the dose-RILT association as statistical interactions: 
changes in cytokines increased or decreased the association between dose and RILT. We 
considered patient factors in a nested fashion, beginning with MLD only and sequentially 
adding clinical characteristics, baseline cytokines, and two- or four-week midtreatment 
cytokines. Clinical factors investigated included administration of concurrent chemotherapy, 
former smoking status, current smoking status, age, sex, simple TNM stage, and Karnofsky 
performance status (KPS). For model-selection purposes, we used data from the same 95 
patients for which complete data was available, to ensure valid between-model comparisons 
(all available patient data was used after model selection).
To account for overfitting and large variability in parameter estimates due to a small ratio of 
sample size to number of predictors, we penalized coefficient estimates, similar to the 
LASSO method [35]. The extent of penalization was selected by maximizing the cross-
validated log-likelihood, which measures overall agreement between model-predicted risks 
and actual prevalence of RILT in our data. We averaged over 250 cross-validations to 
mitigate sensitivity to specific partitions of the data. A larger log-likelihood corresponds to 
Hawkins et al. Page 4
Radiother Oncol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
explaining more variation in risk of RILT between patients, and cross-validating this 
estimate ensures that observed increases are not due to overfitting. Thus, following other 
penalized regression approaches, variables were retained in a model only if their inclusion 
increased the cross-validated log-likelihood. We determined the maximum cross-validated 
log-likelihood within each of the nested models and selected the overall best-performing 
model.
As with any agnostic model-building process, it would be misleading to report statistical 
significance or confidence of this ‘final’ model using standard Wald-based p-values (e.g. 
Section 3.3, [36]). Rather, by virtue of the cross-validated framework, a particular variable’s 
inclusion (or exclusion) from the model reflects significance, or a lack thereof. We also 
report a cross-validated area under the ROC curve (AUC), a measure between 0.5 and 1 that 
quantifies the ability of a model to discriminate the risk of RILT between patients with and 
without RILT. All analyses were conducted in R [37, 38]. Additional details are given in the 
Supplement.
Results
We identified 173 patients who had undergone definitive radiation on four prospective 
institutional protocols. Of these, 26 patients who had been treated with SBRT were 
excluded. Of the remaining 147, complete dose and clinical covariates were known for 125. 
Of these, complete cytokine information pretreatment (Cyt0) and at 2 weeks midtreatment 
(Δ2Cyt) was known for 109, and cytokine data at 4 weeks midtreatment (Δ4Cyt) were known 
for 95. Demographic and clinical characteristics of analyzed patients are shown in Table 1. 
Median MLD was 14.1 Gy (interquartile range 11.6 – 17.2 Gy).
Among the 125 patients with complete dose and clinical information, the incidence of grade 
>= 3 RILT was 8.8% (n=11). Two cases of grade 5 toxicity were recorded. The incidence of 
RILT among all analyzed patients is shown in Supplemental Figure 1. This incidence was 
similar in the 109 patients with known baseline and 2 week midtreatment cytokine levels, 
and in the 95 patients with additional known 4 week midtreatment cytokine levels 
(Supplemental Table 2).
In estimating grade >= 3 RILT by MLD alone, cross-validated log-likelihood and AUC were 
−28.2 and 0.637, respectively (Table 2). For this model, the change in log odds of grade >= 3 
RILT per Gy MLD was 0.096, corresponding to an odds ratio (OR) of 1.101. In other words, 
for each increase in MLD by 1 Gy, the risk of grade >= 3 RILT increased with an OR of 
1.101.
We then fit four nested multivariable models, sequentially incorporating clinical variables 
alone and then adding pretreatment or midtreatment plasma cytokine levels. Augmenting the 
MLD-only model with clinical factors only yielded a decreased cross-validated log-
likelihood of −28.3 (Table 2).
We then further augmented the MLD-only model with both clinical factors and baseline 
cytokine measurements. This yielded a larger cross-validated log-likelihood of −27.6 and a 
cross-validated AUC of 0.669 (Table 2). Of note, each of the 250 log-likelihoods from each 
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individual cross-validation exceeded that of the MLD-only model. Although clinical factors 
did not improve model fit when considered alone, when combined with baseline cytokine 
measurements, concurrent chemotherapy, former smoking status, and age were retained in 
this larger model (Supplemental Table 3). Adding changes in cytokine levels at two or four 
weeks midtreatment did not further improve predictive ability, with log-likelihoods of −27.9 
and −27.8, respectively. Thus, our selected multivariable model incorporated clinical factors 
and baseline, but not midtreatment, cytokine measurements.
According to this multivariable model, when baseline cytokine measurements were at their 
average values, the change in log-odds of grade >= 3 RILT per Gy MLD was 0.118, 
corresponding to an OR of 1.125. In other words, for a patient in which the plasma level of 
each cytokine was at its respective average, the risk of grade >= 3 RILT increased with an 
OR of 1.125 for each increase in MLD by 1 Gy.
Figure 1 compares the estimated cross-validated probabilities of grade >= 3 RILT for the 
MLD-only model against the multivariable model. According to the MLD-only model, the 
median probabilities were 0.089 and 0.107, respectively, for patients who, in truth, did not 
and did have grade >= 3 RILT. For the multivariable model, these median probabilities were 
0.084 and 0.118, respectively, indicating a gain in explained variability. With an increase in 
AUC from 0.637 to 0.669, we expect that our model would be able to correctly distinguish 
between a high-risk and low-risk patient approximately 3.2% more frequently than a MLD-
only model.
Among the 30 cytokines measured, 17 were included in the multivariable model on the basis 
of modifying the dose-RILT association. Thirteen of these decreased the dose-RILT 
association, with GCSF doing so by the largest amount. A one standard deviation increase in 
baseline GCSF levels above the average decreased the log-odds for grade >= 3 RILT per Gy 
MLD from 0.118 to 0.102. This corresponded to a decreased OR of 1.107 from 1.125. In 
other words, when GCSF was elevated one standard deviation above the mean, and all other 
cytokines remained at their averages, each increase in MLD by 1 Gy increased the risk for 
>= 3 RILT not with an OR of 1.125, but of 1.107.
Four cytokines increased the dose-RILT association, with IL1A doing so by the largest 
amount. A one standard deviation increase in baseline IL1A level above the average 
increased the log-odds per Gy from 0.118 to 0.130. This corresponded to an increased OR of 
1.139 compared to 1.125. The modifying effects of all 17 cytokines are plotted in Figure 2. 
The predictive model combines the effect of each cytokine to generate a composite value 
that describes the relative sensitivity to developing grade >= 3 RILT as a function of MLD.
The effect of pretreatment cytokine levels on the dose-RILT relationship is further illustrated 
in Figure 3, which plots the predicted risk of grade >= 3 RILT as a function of MLD. 
Patients with baseline cytokine profiles corresponding to increased sensitivity to MLD 
demonstrate a steeper slope, representing a greater influence of MLD lung toxicity. 
Conversely, patients with profiles corresponding to decreased sensitivity demonstrate a 
flatter slope. The curves cross because the model describes the effect of cytokines on the 
dose-RILT relationship only and not on the risk of RILT directly. As such, cytokine levels 
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influence only the slopes of the lines, which necessitates a point of intersection. This point 
was determined by the best fit of these curves as predicted by the model.
Discussion
In the work described here, we report development a multivariable model combining 
pretreatment plasma cytokine levels, clinical factors, and MLD which demonstrated 
improved prognostication of grade 3 or greater RILT compared to MLD alone. An important 
feature of our approach was that we did not correlate clinical and cytokine data with RILT 
directly, but instead described the effect of these factors on the dose-RILT relationship. In 
other words, the model correlated an individual patient’s pretreatment cytokine and clinical 
profile with a relative sensitivity to developing RILT as a function of MLD.
The improvement in RILT prognostication from the multivariable model was relatively 
modest. Potential reasons for this include measurement of an inadequate number of 
cytokines, suboptimal detection methods, and an inherent limitation of plasma cytokine 
levels to prognosticate RILT. It is possible that plasma cytokine levels do not fully represent 
changes in the local inflammatory milieu, which may influence RILT more directly. 
Performance of this model was likely further limited by the conservative nature of penalized 
regressions in the presence of limited sample sizes. These limitations notwithstanding, our 
findings indicate that the improved prognostication, while modest, was not a statistical 
artifact, as in each of the 250 unique partitions of the data that were used for cross-
validation, the multivariable model was able to explain more variation in risk of grade >= 3 
RILT between patients than the MLD-only model.
Although this multivariable model may have limited clinical applicability in its current form, 
there are important lessons to be taken from this approach. Describing the mechanisms by 
which various patient-specific factors affect the dose-RILT relationship could inform 
decisions regarding radiotherapy planning and dose escalation. With the identification of 
additional factors that interact with the effect of dose on lung or other toxicities, it could be 
possible to identify patients who demonstrate better tolerance of high-dose radiotherapy. In 
such patients, the relative increase in risk from higher radiation dose may be less significant 
than in patients with profiles corresponding to increased sensitivity to dose. In addition, 
understanding how cytokines and other factors affect the dose-toxicity relationship could 
provide a unique framework for investigating biologic function.
The response to radiation-induced injury in the lung-tumor microenvironment is regulated 
by complex networks of inflammatory and fibrotic cytokines [13, 39]. As reviewed in the 
introduction, variations in levels of multiple cytokines have been shown to directly affect the 
risk of RILT. In comparison to those studies, we, by modeling cytokines as modifiers of the 
dose-toxicity relationship, identified a different subset of cytokines that influence RILT. For 
example, while elevated plasma levels of TGFβ1 have been described to correlate with risk 
of RILT, TGFβ1 was not identified in our model as a modifier of the effect of dose on RILT. 
This suggests that the effect of TGFβ1 may be independent of radiation dose, while the 
cytokines identified in our analysis affect risk by a separate, dose-dependent mechanism.
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Of the 17 cytokines that showed prognostic utility in our model, high levels of 13 were 
associated with a decreased effect of dose on risk, while elevation of the remaining 4 was 
associated with an increased effect. The varying effect of these cytokines is not readily 
explained by their respective, currently understood biologic activity. For instance, we found 
some proinflammatory cytokines, including MCP1, SCD40L, IL8, and IL1α, to increase the 
dose-RILT relationship, while others, such as IL1β, IL7, IL12, IL15, and TGFα, decreased 
the effect of dose on risk [39–41]. While these findings do not describe the mechanisms by 
which these cytokines interact with radiation to influence the risk of RILT, they do suggest 
novel functions which should be the focus of future investigation.
Interestingly, only pretreatment, and not midtreatment, plasma cytokine levels were useful in 
our model. This may reflect a baseline state of relative sensitivity to RILT as a function of 
MLD. Alternatively, as lung toxicity often develops on a more chronic timeline, it is possible 
that postreatment levels could provide additional information. However, data obtained after 
completion of radiotherapy would be inherently less useful, as they would not be available to 
guide treatment planning.
As it is well-appreciated that radiation-induced toxicity is influenced by multiple dosimetric, 
clinical, and biologic factors, multivariable prognostic models may better describe these 
risks than single-factor approaches. There are multiple valid methods to correlate prognostic 
variables with an outcome, including the parametric linear model described in this work. 
Another approach is Bayesian network analysis, which explores probabilistic relationships 
among multiple variables by representing their interactions and dependences on a directed 
acyclic graph [42]. Recently, Bayesian network analysis has shown promise as a method to 
estimate the risk of radiation pneumonitis (RP) [43, 44].
Of these, Luo et al. reported an analysis of a cohort of patients that significantly overlaps 
with the patients from this work. There are several important distinctions between that study 
and ours, including use of different primary outcomes (grade 3 or higher RP or clinical 
fibrosis in this analysis versus grade 2 or higher RP by Luo et al.). The statistical modeling 
approaches are also distinct. We utilized penalized logistic regression to model the 
association between the outcomes and covariates. Luo et al. utilized Bayesian network 
analysis. These two approaches differ in several respects. First, the former uses covariates 
(e.g. dose and cytokines) continuously while the latter dichotomizes continuous covariates as 
greater than or less than a threshold. Secondly, the former utilizes penalized regression while 
the latter does not. Imposing a penalty in parameter estimation can improve prediction by 
limiting overfitting. Finally, in addition to modeling covariate-outcome relationships, 
Bayesian network analysis also describes associations between the prognosticators 
themselves. Our paper does not consider associations between covariates.
In the manuscript by Luo et al., the only pretreatment cytokine found to be associated with 
RP was IL15. By comparison, our analysis identified 17 cytokines that interacted with the 
dose-RILT relationship, including IL15, which we observed to decrease the effect of MLD 
on RILT. The fact that these two methods identified different cytokines highlights the 
importance of using multiple approaches to investigate risk factors for radiation-induced 
toxicity, as all analytical tools have their benefits and drawbacks.
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In conclusion, while identifying factors that directly correlate with radiation-induced toxicity 
remains relevant, our work demonstrates that understanding how such factors modify the 
effects of radiation may be particularly useful for selecting patients for dose-escalation and 
informing the investigation of biologic macromolecules. Different approaches for 
multivariable modeling of RILT risk should be employed to improve prognostication and 
uncover topics for further investigation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Estimated probabilities of grade >= 3 lung toxicity by MLD-only versus multivariable 
prediction models. Circles represent cases without RILT, while triangles represent cases with 
RILT. The multivariable model demonstrates improved prediction compared to the MLD-
only model as demonstrated by greater separation of the ‘No RILT’ versus ‘RILT’ 
populations on the Y axis.
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Figure 2. 
Effect on dose-RILT association by increase in cytokine level one standard deviation above 
mean, as expressed in Log OR per Gy. The zero point of the x axis corresponds to no 
modification of the overall dose-RILT relationship, at which state the Log OR of grade >= 3 
RILT increases by 0.118 for each 1 Gy increase in MLD. For these 17 cytokines, when the 
pretreatment level of a given cytokine was elevated 1 standard deviation above its mean 
value, the increase in Log OR for grade >= 3 RILT per 1 Gy MLD was adjusted by the value 
on the x axis corresponding to that cytokine’s position.
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Figure 3. 
Three model fitted dose-RILT curves for predicting grade 3 or greater RILT. The ‘low’, 
‘mid’, and ‘high’ curves represent the first, second, and third quartiles of dose-RILT slopes 
due to cytokine modification.
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Table 1
Baseline demographic, clinical, and treatment characteristics of patients analyzed.
Characteristic Value
Sex
Female 30 (24.0%)
Male 95 (76.0%)
Age
Mean 65.9 years
Median 65.6 years
Range 39.6–85.2 years
Race/Ethnicity
Caucasian 120 (96.0%)
African American 3 (2.4%)
Asian 1 (0.8%)
Not reported 1 (0.8%)
KPS
>= 70 122 (97.6%)
< 70 3 (2.4%)
Smoking Status
Former smoker 61 (48.8%)
Current smoker 53 (42.4%)
Never smoker 7 (5.6%)
Not reported 4 (3.2%)
Group Stage
I 11 (8.8%)
II 13 (10.4%)
III 100 (80.0%)
IV 1 (0.8%)
T Stage
T1 21 (16.8%)
T2 29 (23.2%)
T3 36 (28.8%)
T4 38 (30.4%)
Tx 1 (0.8%)
N Stage
N0 28 (22.4%)
N1 15 (12.0%)
N2 55 (44.0%)
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Characteristic Value
N3 27 (21.6%)
Target Radiation Dose (BED)
Mean 70.2 Gy (87.3 Gy)
Median 70.0 Gy (84.0 Gy)
Range 34.0 – 87.9 Gy (40.8 – 115.5 Gy)
Mean Lung Dose
Mean 14.1 Gy
Interquartile range 11.6 – 17.2 Gy
Range 3.0 – 25.8 Gy
Concurrent Chemotherapy
No 20 (16.0%)
Yes 105 (84.0%)
BED = Biologic equivalent dose. KPS = Karnofsky performance status. Gy = Gray.
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Table 2
Prediction of grade >=3 RILT by MLD and four nested models: Pr(Tox) ~ Dose + Clinical + Cyt0 × Dose + 
ΔtCyt × dose. Models for this analysis were based on the 95 patients with full data available.
AUC Log Likelihood
MLD Only 0.637 −28.2
MLD + Clinical 0.633 −28.3
MLD + Clinical + Cyt0 0.669 −27.6
MLD + Clinical + Cyt0 + Δ2Cyt 0.661 −27.9
MLD + Clinical + Cyt0 + Δ4Cyt 0.668 −27.8
MLD = mean lung dose. Cyt0 = base line cytokine levels. Δ2Cyt = change in cytokine levels at 2 weeks midtreatment. Δ4Cyt = change in cytokine 
levels at 4 weeks midtreatment.
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